DO YOU HAVE LYNCH SYNDROME?

Dana-Farber Cancer Institute is enrolling male patients with known Lynch Syndrome in a clinical trial looking at the frequency of prostate cancer in this group.

MAJOR ELIGIBILITY CRITERIA INCLUDES:

- 40-69 years old
- Positive genetic mutation for Lynch Syndrome (MLH1, MSH2 or MSH6)
- No previous history of prostate cancer
- No previous prostate biopsy for a raised Prostate-Specific Antigen (PSA) level
- No terminal cancer

*Other eligibility criteria may be determined by phone or in person

WHAT WILL HAPPEN IF YOU JOIN? These items are required for our study:

- An initial study visit for eligibility
- Annual donation of blood and urine samples
- Completion of an annual medical history questionnaire

This study may or may not provide direct benefit but we hope it can benefit those in the future. Whether or not you decide to join the study, your current clinical care will not be affected.

Please call or email the research coordinator below for more information about the IMPACT research study:

Brigette Rankin
617-632-4788
BrigetteE_Rankin@dfci.harvard.edu

Sapna Syngal, MD, MPH
Principal Investigator

[logo: Dana-Farber Cancer Institute]